- Home
- RTB vs NRXP Comparison
RTB vs NRXP Comparison
Compare RTB & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RTB | NRXP |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 151.1M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RTB | NRXP |
|---|---|---|
| Price | $8.00 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 124.3K | ★ 601.0K |
| Earning Date | 11-19-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,507.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.83 | $1.65 |
| 52 Week High | $20.75 | $5.06 |
Technical Indicators
Market Signals| Indicator | RTB | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 34.82 |
| Support Level | $8.00 | $2.80 |
| Resistance Level | $11.40 | $3.62 |
| Average True Range (ATR) | 0.97 | 0.13 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 10.83 | 12.39 |
Price Performance
Historical ComparisonAbout RTB RTB Digital Inc. Common Stock
RTB Digital Inc is focused on developing and operating a professional SaaS (Software as a Service) platform that hosts an exclusive coalition of professionally managed online media channels. Its operations include software development, advertising and sponsorship sales, and onboarding third-party content operators (Platform Partners) to publish content on the platform.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.